

For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Takashi Shoda, President and CEO
(Code no.: 4568, First Section, Tokyo, Osaka, and Nagoya Stock Exchanges)
Please address inquiries to Toshiaki Sai, General Manager,
Corporate Communications Department
Telephone: +81-3-6225-1126
<http://www.daiichisankyo.com/>

**THE U.S. DISTRICT COURT HAS ISSUED A DECISION IN OUR FAVOR IN OUR
U.S. PATENT LITIGATION REGARDING BENICAR[®], BENICAR HCT[®] AND
AZOR**

TOKYO, Japan (August 3, 2009) - Daiichi Sankyo Company, Limited announced today that the U.S. District Court in New Jersey has issued a decision in our U.S. patent litigation against Mylan* upholding the validity of our patent covering the Benicar[®], Benicar HCT[®] and AZOR[®] products. We had initiated the litigation against Mylan in response to Abbreviated New Drug Applications (“ANDAs”) filed by Mylan seeking to market generic versions of those products before the expiration of our patent, which expires in 2016.

Olmesartan medoxomil, an active ingredient in Benicar[®], Benicar HCT[®] and AZOR[®], is an angiotensin II receptor antagonist that Daiichi Sankyo independently developed, and is marketed in over 50 countries as an antihypertensive drug which suppresses vasoconstriction by affecting the rennin-angiotensin system to control blood pressure.

*Note:

“Mylan” refers to Mylan Inc. (HQ: Pennsylvania) and Matrix Laboratories, Limited (HQ: India), a subsidiary of Mylan.

###

About Daiichi Sankyo Company, Limited

A global pharma innovator, Daiichi Sankyo Co., Ltd., was established in 2005 through the merger of two leading Japanese pharmaceutical companies. This integration created a more robust organization that allows for continuous development of novel drugs that enrich the quality of life for patients around the world. A central focus of Daiichi Sankyo's research and development are thrombotic disorders, malignant neoplasm, diabetes mellitus, and autoimmune disorders. Equally important to the company are hypertension, hyperlipidemia or atherosclerosis and bacterial infections. For more information, visit www.daiichisankyo.com.